Back

Effects of dapagliflozin on new-onset diabetes in patients with heart failure: a pooled, participant-level analysis of the DAPA-HF and DELIVER trials

12 May 2024 (14:30 - 14:45)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award (YIA) Clinical Cardiology Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mats Christian Hoejbjerg Lassen

Herlev and Gentofte Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Tricuspid regurgitation disease stages and treatment outcomes after transcatheter tricuspid valve repair
Doctor F. Schlotter (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Heart Failure and autoimmune disease: a Nationwide Cohort Study
Ms G. Sun (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Can SGLT2i use decrease the risk of atrial fibrillation in patients with heart failure with reduced ejection fraction: a retrospective cohort study
Doctor J. Alejandro (Baltimore, US)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award (YIA) Clinical Cardiology
Video

The Event

Event poster

Heart Failure 2024

12 May 2024 14:30 CET
You may be interested in
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial
thumbnail
Congress Presentation
Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources